A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)

NCT02657434 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

578

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Atezolizumab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed

Sponsor

Hoffmann-La Roche